State of the Art on Approved Cystic Fibrosis Transmembrane Conductance Regulator (<i>CFTR</i>) Modulators and Triple-Combination Therapy

• Autors principals: Aniello Meoli (Autor), Valentina Fainardi (Autor), Michela Deolmi (Autor), Giulia Chiopris (Autor), Francesca Marinelli (Autor), Caterina Caminiti (Autor), Susanna Esposito (Autor), Giovanna Pisi (Autor)
• Format: Llibre
• Publicat: MDPI AG, 2021-09-01T00:00:00Z.
• Matèries: article
• Accés en línia: Connect to this object online.

Cystic fibrosis (CF) is the most common life-limiting inherited disease in Caucasian populations, affecting approximately 80,000 people worldwide. CF is a complex multi-organ monogenic autosomal recessive disorder caused by a mutation in cystic fibrosis transmembrane conductance regulator (<i>...